TR
Terumo Corporation
TRUMY · OTC
$14.16 -3.52% (-$0.52)
1M -12.32%
Market Cap ¥3.38T
P/E Ratio 20.35x
Div. Yield 1.18%
ROE 10.70%
Bulios Fair Price
$7.19
49.2% downside
Current Price
$14.16
Undervalued Fair Value Overvalued
According to Bulios Fair Price, TRUMY is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
5/9Valuation
66 /100
Fair P/E 20.35x
PEG 2.90x
EV/EBITDA 11.55x
Growth
81 /100
Growing EPS growth 10.41%
Book val. growth 10.57%
Rev. growth 13.79%
Profitability
85 /100
Strong Gross margin 53.03%
FCF margin 16.16%
Net margin 13.81%
Quality
46 /100
Average ROIC 7.29%
Asset turnover 0.51x
ROE 10.70%
Debt
100 /100
Low Debt/Equity 0.26x
Net debt/EBITDA 0.41x
Current ratio 2.19x
Stability
77 /100
Stable Beta 0.23x
Profitable years 6
Rev. volatility 2.44%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about TRUMY
Online
Sector
Healthcare
Industry
Medical - Devices
CEO
Hikaru Samejima
Employees
30,207
Headquarters
Tokyo
Upcoming events
11 NOV
Earnings
Upcoming earnings report